Telix Pharmaceuticals (NASDAQ:TLX) Trading Up 5.5% – Here’s What Happened

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) were up 5.5% during mid-day trading on Friday . The stock traded as high as $7.52 and last traded at $7.52. Approximately 116,986 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 239,849 shares. The stock had previously closed at $7.13.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TLX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Citigroup upped their price objective on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Finally, Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Stock Up 6.2%

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock’s 50 day moving average is $7.32 and its two-hundred day moving average is $8.99.

Telix Pharmaceuticals (NASDAQ:TLX) last announced its earnings results on Thursday, February 19th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $414.02 million for the quarter, compared to analyst estimates of $421.50 million. As a group, research analysts expect that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals in the 4th quarter worth $89,000. IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $213,000. OLD Mission Capital LLC purchased a new position in Telix Pharmaceuticals during the fourth quarter worth about $111,000. Finally, Private Advisor Group LLC raised its holdings in Telix Pharmaceuticals by 67.3% during the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock worth $403,000 after purchasing an additional 16,945 shares in the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.